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Background & aims: Many COPD patients have a reduced exercise capacity and mechanical efﬁciency and
are at increased cardiometabolic risk. This study aimed to assess acute and 7-days effects of dietary
nitrate on mechanical efﬁciency, exercise performance and cardiac biomarkers in patients with COPD.
Methods: This double-blind, randomized cross-over placebo controlled trial included 20 mild-to-
moderate COPD patients (66.6 ± 7.5 years) with moderate exercise impairments and decreased me-
chanical efﬁciency, normal BMI (26 ± 3 kg/m2) but high prevalence of abdominal obesity (83.3%). Sub-
jects were randomly allocated to the treatment order of 7 days sodium nitrate ingestion (~8 mmol/day)
and 7 days placebo (NaCl solution) or vice versa, separated by a washout period. Before (Day-1) and after
(Day-7) both intervention periods resting metabolic rate and the metabolic response during submaximal
cycle ergometry, cycling endurance time, plasma nitrate and nitrite levels, cardiac plasma biomarkers
(e.g. cardiac troponin T, Nt-proBNP and creatinine kinase) and blood pressure were measured. Subse-
quently, gross, net and delta mechanical efﬁciency were calculated.
Results: Plasma nitrate and nitrite concentrations increased at Day-1 and Day-7 after sodium nitrate but
not after placebo ingestion. Systolic and diastolic blood pressure did not change following nitrate
ingestion. Furthermore, no differences were observed in gross, net, and delta mechanical efﬁciency
during submaximal exercise, cycling endurance time and cardiac biomarkers between nitrate and pla-
cebo on Day-1 and Day-7. Meta-analysis of all available studies in COPD also showed no beneﬁcial effect
of beetroot juice on systolic and diastolic blood pressure.
Conclusion: Acute as well as 7-days sodium nitrate supplementation does not modulate mechanical
efﬁciency, blood pressure or cardiac biomarkers in mild-to-moderate COPD patients.
© 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.dy mass index; BRJ, beetroot juice; CK, creatinine kinase; CKD-EPI, estimated glomerular ﬁltration rate; COPD, chronic
Ray Absorptiometry; FEV1, forced expiratory volume in 1 s; FFMI, fat free mass index; FVC, forced vital capacity; HDL,
el assessment to estimate insulin resistance; Hs-CRP, high-sensitive C-reactive protein; Hs-TNT, high-sensitive troponin
iency; MVPA, moderate to vigorous physical activity; NaNO3, sodium nitrate; NO, nitric oxide; NT-proBNP, N-terminal
PR, pulmonary rehabilitation; SCT, submaximal cycling test; SMI, skeletal muscle mass index; REE, resting energy
arbon dioxide productions; VO2, oxygen consumption; Wmax, maximal work load.
aastricht, The Netherlands. Fax: þ0031 43 3875051.
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Chronic obstructive pulmonary disease (COPD) is a progressive
lung disease characterized by persistent airﬂow obstruction
resulting from enhanced inﬂammation in the airways [1]. Besides
the respiratory impairment, extrapulmonary manifestations and
comorbidities inﬂuence disease burden and mortality [1]. Common
comorbidities include cardiovascular disease and metabolic syn-
drome [2,3]. Cardiometabolic risk is not only increased in obese
patients but also in normal weight COPD patients with low muscle
mass and abdominal obesity [4,5]. Furthermore, patients with
COPD have lower mechanical efﬁciency, i.e. the proportion of work
accomplished to energy expended, compared to healthy controls
[6e8], possibly due to an increased oxygen cost of breathing [6] and
impaired muscle mitochondrial metabolism [8e11]. As a lower
mechanical efﬁciency can contribute to impaired exercise perfor-
mance and hamper efﬁcacy of aerobic exercise training, patients
with COPD might beneﬁt from interventions targeting mechanical
efﬁciency.
Nitrate is an interesting nutrient that might improve both me-
chanical efﬁciency and cardiovascular health in COPD. Dietary ni-
trate is reduced to nitrite which subsequently is converted to nitric
oxide (NO) [12]. As a result of dietary nitrate intake, NO availability
will be increased which can have vasodilatory effects that can lower
blood pressure and affect body temperature [13]. Indeed, two meta-
analyses showed lowered blood pressure in adults with or without
comorbidities after inorganic nitrate or beetroot juice (BRJ) sup-
plementation [14,15]. Besides beneﬁcial effects on blood pressure,
increased NO availability can modulate muscle-related processes
including muscle contractility, glucose homeostasis, blood ﬂow,
mitochondrial respiration and biogenesis [16]. A side effect of an
increased blood ﬂow in the extremities is that it may warm the skin
and facilitate extra heat loss, which has to be compensated by a
higher metabolic rate, or may lead to a reduction in body core
temperature. Recently, a meta-analysis demonstrated improved
endurance exercise performance following dietary nitrate ingestion
in healthy adults [17]. Furthermore, oxygen cost of exercise has been
shown to decrease after dietary nitrate intake, without affecting
resting metabolic rate [18]. We therefore hypothesized that dietary
nitrate might also modulate mechanical efﬁciency in COPD.
Dietary nitrate is mostly present in green leafy and root vege-
tables and inmost research it is applied in the form of BRJ. Although
beneﬁcial physiological effects of BRJ are ascribed to the high ni-
trate content [19], it could be argued that nitrate is not the active
nutrient after all or that nitrate interacts with other compounds in
BRJ which cause the beneﬁcial effects. In order to investigate the
effects of nitrate alone, without needing to account for unknown
interactions with other interventional compounds in the solution,
sodium nitrate would be preferred. In healthy adults, a multiple
dosing day strategy was more efﬁcacious for improving exercise
performance than an acute dose [20]. If this is also the case in pa-
tients with COPD it would be interesting to compare the acute ef-
fect with the multiple dosing day effects. We hypothesized that
sodium nitrate modulates mechanical efﬁciency, improves exercise
performance and improves cardiac biomarkers. Therefore, the aim
of this study was to assess the acute and 7-days effects of sodium
nitrate supplementation on mechanical efﬁciency, exercise per-
formance and cardiac biomarkers in patients with COPD.
2. Methods
2.1. Study design and subjects
This study was a double-blind, randomized cross-over placebo
controlled trial including 20 clinically stable COPD patients with adecreased mechanical efﬁciency based on screening of the ratio
between peak oxygen consumption (VO2)/maximal work load
(Wmax) during incremental cycling test (10 mL/min/W) [21].
Patients were recruited via advertisements in local newspapers,
between 2015 and 2016. Exclusion criteria were sodium intake
limitation, long-term oxygen therapy, severe renal impairment
(glomerular ﬁltration rate <30 mL/min), medications that might
develop a risk for hypotension in combination with nitrate (i.e.
PDE-5 inhibitors and nitrate-containing/releasing medication) and
contra-indications for performing (sub-)maximal cycle test. The
study was registered at clinicaltrials.gov (NCT02084758) and was
approved by the Medical Ethics Committee from Maastricht Uni-
versity Medical Centre þ (MUMCþ [NL47701.068.1/MEC 14-3-
016]). All patients gave their written informed consent.
2.2. Supplementation protocol
Before the start of the study, subjects visited the laboratory for
a screening to measure lung function using forced spirometry
(Masterlab, Jaeger, Würzburg, Germany) and to perform an in-
cremental cycling ergometry test on an electromagnetic braked
cycle ergometer (Ergoselect 200, Ergoline, Blitz, Germany) (see
supplemental material for detailed methodology). Eligible sub-
jects were randomly allocated to the treatment order of ingesting
a daily dose of sodium nitrate (NaNO3 [BASF, Ludwigshafen, Ger-
many]) and placebo (NaCl [Frisia Zout BV, Harlingen, The
Netherlands) dissolved in 140 mL water. Randomisation was
performed by an independent researcher from the MUMCþ and
both subjects and researchers were blinded for the treatments till
the end of the study. The nitrate intervention period consisted of a
daily dose of 680 mg NaNO3 (which equals 496 mg or ~8 mmol of
nitrate) ingestion for 7 days. The placebo was provided in an equal
daily dose of 680 mg NaCl ingestion for 7 days. Both intervention
periods were separated by at least 7 days wash-out (Fig. 1). The
ﬁrst supplemental bolus was consumed in the laboratory at the
ﬁrst test-day, 2.5 h before the submaximal cycling test (Fig. 2). The
last bolus was consumed in the laboratory at day 7, also 2.5 h
before the submaximal cycling test. Test-days were separated by
the subjects consuming a supplemental bolus for 5 consecutive
days.
Subjects were requested to abstain from foods naturally high in
nitrate and to avoid using antibacterial mouthwash during the
intervention periods [22].
2.3. Test-days
On the morning of each test-day, subjects came to the labora-
tory in a fasted state. Subjects orally ingested a temperature
telemetry medical grade capsule (EQ02 SEW, Philips Respironic
Massachusetts, USA) to measure the core temperature and after-
wards iButton® dataloggers (DS1923, Maxim USA) were attached
to 20 skin sites to measure the mean skin temperature. Subse-
quently, the ventilated hood system (Omnical; Maastricht Uni-
versity, Maastricht, The Netherlands) was used to measure resting
energy expenditure (REE), an automated blood pressure monitor
was used to measure the blood pressure (Omron Healthcare Inc,
Field Court Lake Forest, USA) and an intravenous cannula was
inserted into an antecubital vein to obtain a fasted blood sample
(T0). After this, subjects received their supplemental beverage
(Fig. 2) and one hour later they received a standardized liquid
breakfast (125 mL Respifor, Nutricia, Zoetermeer, Netherlands). A
submaximal cycle ergometry test at 50% Wmax for 10 min, at a
ﬁxed pedal rate of 60e70 RPM was performed 2.5 h after ingestion
of the beverage. After 10 min, workload was increased to 70%
Wmax and subjects were instructed to cycle until (symptom
screening
inclusion
accelerometer
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Fig. 1. Schematic illustration of the study protocol.
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Fig. 2. Schematic illustration of the test-day. Abbreviations: REE, Resting energy expenditure; SCT, submaximal cycling test; DXA, Dual-energy X-ray absorptiometry.
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delta mechanical efﬁciency were calculated according to Ettema
et al. [23]. The abbreviated Weir formula was used to calculate
energy expenditure during exercise [24]. Repeated blood pressure
measurements and blood draws were performed 90 (T1) and 150
(T2) min after the beverage ingestion, immediately after the cycle
test (T3), and subsequently after 30 (T4) and 60 min (T5).
Only on the ﬁrst test-day Dual Energy X-Ray Absorptiometry
(DEXA, Hologic, Discovery A, QDR Series, Bedford, MA, USA) was
applied to assess body composition. During the 5 supplementation
days, patients wore an accelerometer to verify similar physical ac-
tivity (PA) levels during both intervention periods.2.4. Plasma analysis procedures
Blood was sampled in Lithium-Heparin S-Monovette® tubes
(Sarstedt, Nümbrecht, Germany). Tubes were immediately centri-
fuged at 1000 g for 10 min, at 4 C after which the aliquots were
snap-frozen in liquid nitrogen and stored at 80 C for subsequent
analysis of plasma nitrate and nitrite using gas-phase chem-
iluminescence technique as was previously described [25]. Brieﬂy,
nitrate and nitrite concentrations were determined based on their
reduction to NO. Upon the NO reaction with ozone, nitrogen di-
oxide is formed and during this production NO is quantiﬁed by
detecting the light emitted using a thermoelectrically cooled, red-
sensitive photomultiplier tube, housed in a gas-phase chem-
iluminescence NO analyzer (Sievers Instruments, NOA™ 280i,
Analytix). Furthermore, plasma was used to determine cardiac
biomarkers high sensitive troponin T (Hs-TNT), N-terminal pro-B-
type natriuretic peptide (NT-proBNP) and creatine kinase (CK)
(see supplemental material for details). Furthermore, baseline
glucose and lipid proﬁles, estimated glomerular ﬁltration rate
(CKD-EPI) and high-sensitive C-reactive protein (Hs-CRP) were
determined.2.5. Statistics
Mechanical efﬁciency and temperature data were analyzed by
two-way repeated measures ANOVA with treatment (nitrate and
placebo) and test-day (day 1 and day 7) as within subject factors.
Statistical analysis of all plasma and blood pressure data were
performed using three-way repeated measures ANOVA with
treatment (nitrate and placebo), test-day (day 1 and day 7) and
time (T0, T1, T2, T3, T4 and T5) as within subject factors. All data
were analyzed using Statistical Package for the Social Sciences
(SPSS version 22 for Windows, IBM Corp., Armonk, USA) and data
are presented as mean ± SD. A p-value <0.05 was considered sta-
tistically signiﬁcant.
In order to compare results of the current study with previous
literature in COPD a meta-analysis was performed as described in
the supplemental material. Brieﬂy, Pubmed database was used to
ﬁnd relevant articles on dietary nitrate in COPD. Data on systolic
and diastolic blood pressure of both nitrate and placebo group were
extracted. If a study did not show mean ± SD for the suggested
outcomes, original authors were contacted for additional infor-
mation. Subsequently, standardized mean differences (95% conﬁ-
dence intervals (CI)) have been calculated as Hedges' g due to the
small sample sizes in the studies. A random effects model was used
because of the considerable variability in several experimental
factors (e.g. dose, duration and measurement) across studies [26].
The meta-analysis was performed with the Stata software package
(StataCorp. 2015. Stata Statistical Software: Release 14. College Sta-
tion, TX: StataCorp LP).3. Results
In total 20 subjects were randomized in the study and 18
eventually ﬁnished the full study (Fig. 3). Subject characteristics are
presented in Table 1. The study population comprised a normal to
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COPD (FEV1%pred 69.2 ± 16.3). Baseline gross mechanical efﬁ-
ciency during the incremental cycling test was 21.3 ± 3.4%, which
was signiﬁcantly lower than a healthy age matched control group
from a previous study of our group (FEV1: 113.3 ± 14.6 %predicted,
grossmechanical efﬁciency: 24.8 ± 6.1%, p¼ 0.049) [10]. Abdominal
obesity was present in 83.3% of the patients and four patients had
lowmuscle mass. Plasma markers of lipid and glucose metabolism,
kidney function and Hs-CRP were within normal range. Subjects
reported that they had consumed all doses of the supplements.
Both supplements were well-tolerated and no patients reported
any deleterious side effects.
3.1. Plasma nitrate and nitrite
Baseline plasma concentration of nitrate (58 ± 36 mM, p¼ 0.006)
was ~2-fold increased at Nitrate day 7 (133 ± 106 mM), while no
differences were observed in plasma nitrite (Fig. 4). Following
ingestion of nitrate, plasma nitrate increased to the same extent at
Nitrate day 1 (T0 vs T1; 331 ± 54 mM, p < 0.001) and day 7 (T0 vs T1;
339 ± 57 mM, p < 0.001) and remained elevated throughout the
test-day. Baseline plasma nitrite was ~2-fold increased after the
nitrate ingestion at Nitrate day 1 (T0 to T1; 256 ± 132 to
634 ± 345 nM; p < 0.001) as well as Nitrate day 7 (T0 vs T1;
245 ± 165 to 501 ± 358 nM; p ¼ 0.003) and also remained elevated
throughout the test-day. Plasma nitrate and nitrite levels were not
different at Placebo day 1 and 7.Assessed for eligibility
(n=87)
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Completed study
(n=18)
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Fig. 3. Inclusion3.2. Submaximal cycling, resting energy expenditure and body
temperatures
During cycling at 50% and 70%Wmax, baseline grossmechanical
efﬁciency (Placebo day 1) was 15.9 ± 2.8% and 17.6 ± 2.8% and
baseline net mechanical efﬁciency was 20.4 ± 3.0% and 21.4 ± 2.9%,
respectively. Following nitrate ingestion, both gross and net me-
chanical efﬁciency were not different at Nitrate day 1 and day 7,
both at 50% and 70% Wmax, compared to placebo (Table 2). Delta
mechanical efﬁciency was also not different between the nitrate
and placebo treatment. Furthermore, no differences in VO2, VCO2,
respiratory exchange rate and energy expenditure in rest as well as
during cycling at 50% and 70% Wmax were observed between ni-
trate and placebo, both at day 1 and day 7. Furthermore, the cycling
endurance time was not different between the interventions. Skin
and core temperature during the REE measurement and the sub-
maximal cycling test were not different between nitrate and pla-
cebo at both day 1 and day 7.
3.3. Blood pressure
Baseline systolic blood pressure was 140 ± 14 mmHg and
baseline diastolic blood pressure was 81 ± 10 mmHg. Following
acute and 7-days nitrate ingestion blood pressure as well as heart
rate did not change compared to placebo (Table 3). At both Nitrate
and Placebo day 1 and day 7, systolic blood pressure decreased
signiﬁcantly (T0 vs T4; 13 ± 12 mmHg, p < 0.001) during theined to participate (n=43)
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Table 1
Subject characteristics (n ¼ 18).
N ¼ 18
Age, y 66.6 ± 7.5
Males, n (%) 13 (72.2)
Smoking status
Current smokers, n (%) 8 (44.4)
Former smokers, n (%) 10 (55.6)
FEV1, %pred 69.2 ± 16.3
FVC, %pred 97.8 ± 18.5
FEV1/FVC, % 54.2 ± 9.8
BMI, kg/m2 25.9 ± 3.4
FFMI, kg/m2 17.3 ± 1.9
SMI, kg/m2 7.3 ± 0.9
Low SMI, n (%) 4 (22.2)
Fat percentage, % 30.7 ± 5.6
Abdominal obesity, n (%) 15 (83.3)
BMD, g/cm2 1.1 ± 0.1
Peak VO2, ml/min/kg 19.7 ± 4.0
Peak VO2, %pred 79 (70e87)
Wmax, W 115 ± 34
Wmax, %pred 76.1 ± 18.9
Maximal heart rate, beats/min 136 ± 17
Cholesterol, mmol/L 4.87 ± 0.92
HDL cholesterol, mmol/L 1.2 (1.1e1.5)
LDL cholesterol, mmol/L 2.75 ± 0.88
Triglycerides, mmol/L 1.2 (0.9e1.7)
Glucose,mmol/L 5.96 (5.55e6.72)
Insulin, mU/L 5.7 ± 3.2
HOMA-IR 1.7 ± 1.0
Kreatinine, mmol/L 81.8 ± 19.9
CKD-epi, ml/min/1.73m2 80.0 ± 14.2
Hs-CRP, mg/L 2.6 (0.9e6.0)
Data are shown as mean ± SD unless indicated otherwise.
Abbreviations: BMD, bone mineral density; CKD-epi, Chronic Kidney Disease
Epidemiology Collaboration; FEV1, forced expiratory volume in 1 s; FFMI, fat free
mass index; FVC, forced vital capacity; Hs-CRP, high-sensitive C-reactive pro-
tein; SMI, skeletal muscle mass index; VO2, oxygen consumption; Wmax,
maximal work load.
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Fig. 4. Plasma nitrate and nitrite concentrations on day 1 and day 7 for the placebo
and nitrate intervention at different timepoints. Blood draws were performed at
baseline (T0), 90 (T1) and 150 (T2) minutes after the beverage ingestion, immediately
after the cycle test (T3), and subsequently after 30 (T4) and 60 min (T5). Values are
mean ± SEM; n ¼ 17. *Signiﬁcantly different from placebo (p < 0.05). #Signiﬁcantly
different from nitrate day 7 (p < 0.05). ySigniﬁcantly different from T0 (p < 0.05).
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baseline while diastolic blood pressure remained unchanged.
Furthermore, heart rate was signiﬁcantly increased (T0 vs T3;
41 ± 15 beats/min, p < 0.001) directly after the submaximal cycling
test and remained elevated during the resting period after cycling
(T0 vs T4; 13 ± 9 and T0 vs T5; 8 ± 7 beats/min, respectively, both
p < 0.001) at both day 1 and 7 of nitrate and placebo ingestion.
3.4. Cardiac biomarkers
No differences were observed in cardiac markers Hs-TNT, NT-
proBNP and CK following acute and 7-days nitrate ingestion
compared to placebo (Fig. 5). All cardiac markers were increased
after exercise (T2 vs T3; Hs-TNT 0.4 ± 0.1 ng/mL, p ¼ 0.011; NT-
proBNP 1.7 ± 0.5 rmol/L, p ¼ 0.003; CK 8.1 ± 1.7, p < 0.001).
Furthermore, Hs-TNTwas higher at baseline (T0) compared to other
time points at the test-day.
3.5. Physical activity levels
Total physical activity level as well as physical activity pattern
was not different during nitrate and placebo ingestion (Table 4).
3.6. Meta-analysis
Main characteristics of the studies are summarized in
Supplemental Table 1. In total 94 patients participated in the
included studies. The mean age range was 65e70 years and pa-
tients were normal to overweight (mean BMI: 25e29 kg/m2) with
mild-to-moderate COPD (mean FEV1: 43e62 %predicted). Allstudies used beetroot juice as a nitrate-rich supplement, with a
nitrate-dose ranging between 6.77 and 12.0 mmol/day. Following
the meta-analysis the standardized mean difference was 0.03
(95% CI -0.32 to 0.26) for systolic blood pressure and 0.24 (95% CI
-0.55 to 0.08) for diastolic blood pressure, showing a small but non-
signiﬁcant effect in favour of dietary nitrate (Fig. 6).4. Discussion
To our knowledge this is the ﬁrst study investigating the acute as
well as the 7-days effects of sodium nitrate supplementation on
mechanical efﬁciency and cardiac biomarkers in mild-to-moderate
COPD patients. Acute as well as 7-days nitrate supplementation did
not alter mechanical efﬁciency, despite clear and anticipated
elevated plasma nitrate and nitrite levels. Furthermore, exercise
performance, blood pressure, cardiac biomarkers Hs-TNT, NT-
proBNP and CK, skin and core temperatures and ﬁnally REE were
Table 2
Steady-state values of energy expenditure during rest and submaximal cycling after nitrate and placebo ingestion.
Nitrate Placebo p-value
Day 1 Day 7 Day 1 Day 7
Resting energy expenditure
VO2, mL/min 231 ± 31 233 ± 31 234 ± 30 237 ± 34 0.825
VCO2, mL/min 196 ± 28 194 ± 23 193 ± 21 198 ± 26 0.062
VO2, mL/min/kg 3.0 ± 0.3 3.0 ± 0.2 3.0 ± 0.2 3.1 ± 0.2 0.823
VCO2, mL/min/kg 2.5 ± 0.3 2.5 ± 0.3 2.5 ± 0.3 2.6 ± 0.3 0.083
RER 0.85 ± 0.05 0.84 ± 0.05 0.83 ± 0.04 0.84 ± 0.05 0.195
Energy expenditure, kcal/min 1.12 ± 0.15 1.12 ± 0.14 1.13 ± 0.14 1.14 ± 0.16 0.538
Core temperature, Cy 36.8 ± 0.2 36.8 ± 0.3 36.9 ± 0.3 36.7 ± 0.6 0.313
Skin temperature, C 32.9 ± 0.5 33.0 ± 0.5 33.0 ± 0.4 33.0 ± 0.5 0.827
Submaximal cycling at 50% Wmax
VO2, mL/min 1034 ± 182 1032 ± 191 1039 ± 182 1033 ± 191 0.806
VCO2, mL/min 945 ± 184 950 ± 195 949 ± 175 953 ± 180 0.951
VO2, mL/min/kg 13.3 ± 2.4 13.3 ± 2.5 13.4 ± 2.3 13.3 ± 2.2 0.622
VCO2, mL/min/kg 12.2 ± 2.4 12.2 ± 2.6 12.2 ± 2.3 12.2 ± 2.1 0.761
RER 0.91 ± 0.04 0.92 ± 0.06 0.91 ± 0.04 0.92 ± 0.04 0.744
Energy expenditure, kcal/min 5.07 ± 0.91 5.07 ± 0.96 5.10 ± 0.90 5.08 ± 0.94 0.840
Gross ME, % 16.0 ± 2.8 16.0 ± 2.7 15.9 ± 2.8 16.0 ± 3.1 0.626
Net ME, % 20.6 ± 3.2 20.6 ± 2.8 20.4 ± 3.0 20.7 ± 3.4 0.647
Core temperature, C 37.0 ± 0.3 36.9 ± 0.4 37.1 ± 0.4 36.7 ± 0.7 0.089
Skin temperature, C 31.8 ± 0.4 31.9 ± 0.6 31.9 ± 0.6 32.0 ± 0.6 0.651
Submaximal cycling at 70% Wmax
VO2, mL/min 1302 ± 274 1315 ± 291 1319 ± 273 1323 ± 275 0.633
VCO2, mL/min 1246 ± 298 1260 ± 307 1239 ± 278 1269 ± 276 0.506
VO2, mL/min/kg 16.7 ± 3.7 16.9 ± 3.9 16.9 ± 3.6 16.9 ± 3.9 0.558
VCO2, mL/min/kg 16.0 ± 3.9 16.1 ± 4.0 15.9 ± 3.7 16.2 ± 3.5 0.583
RER 0.95 ± 0.05 0.95 ± 0.05 0.93 ± 0.06 0.96 ± 0.04 0.195
Energy expenditure, kcal/min 6.45 ± 1.39 6.51 ± 1.47 6.51 ± 1.37 6.56 ± 1.37 0.868
Gross ME, % 17.8 ± 2.7 17.6 ± 2.6 17.6 ± 2.8 17.5 ± 3.0 0.839
Net ME, % 21.7 ± 2.8 21.5 ± 2.5 21.4 ± 2.9 21.3 ± 3.1 0.757
Delta ME, % 26.9 ± 4.8 24.7 ± 3.6 26.6 ± 6.8 24.3 ± 3.9 0.997
Cycling time, min 1186 ± 402 1316 ± 440 1331 ± 426 1300 ± 387 0.077
Core temperature, C 37.2 ± 0.3 37.2 ± 0.4 37.4 ± 0.4 37.0 ± 0.9 0.066
Skin temperature, C 32.0 ± 0.5 32.0 ± 0.6 32.0 ± 0.4 32.1 ± 0.6 0.763
Data are shown as mean ± SD.
Abbreviations: ME, mechanical efﬁciency; VO2, oxygen consumption; VCO2, carbon dioxide production; RER, respiratory exchange rate.
Table 3
Blood pressure and heart rate after nitrate or placebo ingestion (n ¼ 18).
Nitrate Placebo p-value
Day 1 Day 7 Day 1 Day 7
Systolic blood pressure, mmHg
T0 137 ± 15 135 ± 18 137 ± 15 137 ± 21 0.613
T1 132 ± 17 130 ± 18 134 ± 15 138 ± 21 0.138
T2 135 ± 19 135 ± 18 135 ± 18 138 ± 20 0.655
T3 152 ± 33 148 ± 22 145 ± 31 151 ± 26 0.165
T4 123 ± 19* 122 ± 16* 124 ± 17* 123 ± 16* 0.820
T5 125 ± 17* 125 ± 15* 126 ± 13* 130 ± 15 0.278
Diastolic blood pressure, mmHg
T0 79 ± 9 78 ± 11 79 ± 13 79 ± 11 0.639
T1 74 ± 10* 74 ± 11 75 ± 10 77 ± 12 0.368
T2 78 ± 8 78 ± 9 80 ± 10 78 ± 10 0.348
T3 81 ± 13 80 ± 14 77 ± 11 78 ± 11 0.635
T4 77 ± 13 73 ± 9 78 ± 11 76 ± 10 0.535
T5 76 ± 11 76 ± 12 77 ± 10 81 ± 10 0.188
Heart rate, beats/min
T0 64 ± 8 64 ± 8 64 ± 8 64 ± 7 0.862
T1 69 ± 11 68 ± 11 70 ± *9* 67 ± 9 0.236
T2 68 ± 9* 68 ± 10 67 ± 9 67 ± 10 0.762
T3 106 ± 12* 106 ± 17* 106 ± 13* 104 ± 18* 0.676
T4 77 ± 10* 76 ± 10* 78 ± 13* 77 ± 12* 0.980
T5 72 ± 10* 71 ± 9* 72 ± 13* 72 ± 12* 0.771
Measurements were performed at baseline (T0), 90 (T1) and 150 (T2) minutes after
the beverage ingestion, immediately after the cycle test (T3), and subsequently after
30 (T4) and 60 min (T5).
*Signiﬁcantly different from T0 (p < 0.05). Values are mean ± SD; n ¼ 18.
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our hypothesis.
We expected improved mechanical efﬁciency after sodium ni-
trate ingestion as nitrate is suggested to decrease VO2 during ex-
ercise in healthy subjects, without alterations in REE [18]. However,
in the current study both mechanical efﬁciency and VO2 during
submaximal exercise were not affected after sodium nitrate
ingestion. Since most studies showing beneﬁcial effects of dietary
nitrate on oxygen requirements during exercise are performed in
healthy young individuals it is possible that VO2 kinetics cannot be
altered at an older age or in a clinically compromised older popu-
lation. Two studies have been performed in healthy older subjects
with conﬂicting results [27,28]. After nitrate rich BRJ, one study
showed a reduced VO2 mean response time in the transition from
standing rest to treadmill walking which might indicate a reduced
reliance on nonoxidative metabolic processes across the transition
from a lower to a higher metabolic rate [27]. However, the oxygen
cost of exercise remained unchanged, corresponding to another
study in which no changes in resting, submaximal and maximal
VO2 during incremental cycling were found [28]. Furthermore, in
older patients with heart failure [29], type 2 diabetes mellitus [30]
and COPD [31e34] most studies could not ﬁnd improved VO2 ki-
netics after BRJ ingestion. Only one study showed slightly
decreased isotime VO2 during submaximal cycling following acute
BRJ ingestion [32]. Since patients with COPD spend probably more
time walking instead of cycling it could be questioned whether the
cycling test was the most optimal test to ﬁnd beneﬁcial effects of
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Fig. 5. Plasma high sensitive troponin T, NT-proBNP and creatinine kinase on day 1 and
day 7 for the placebo and nitrate intervention at different timepoints. Blood draws
were performed at baseline (T0), 90 (T1) and 150 (T2) minutes after the beverage
ingestion, immediately after the cycle test (T3), and subsequently after 30 (T4) and
60 min (T5). Values are mean ± SEM; n ¼ 17. No signiﬁcant differences were observed
between nitrate versus placebo and day 1 versus day 7. *Signiﬁcantly different from T0
(p < 0.05). Abbreviation: NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Table 4
Physical activity levels during nitrate and placebo intervention (n ¼ 17).
Placebo Nitrate p-value
Total activity, counts/min 204 ± 106 214 ± 104 0.528
Time spent in sedentary PA, % of wear time 68.5 ± 12.6 68.7 ± 9.6 0.866
Time spent in lifestyle PA, % of wear time 23.8 ± 8.1 23.2 ± 5.4 0.573
Time spent in MVPA, % of wear time 7.8 ± 5.4 8.1 ± 5.0 0.605
Data are shown as mean ± SD.
Abbreviations: PA, physical activity; MVPA, moderate to vigorous physical activity.
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study showed good reproducibility of the submaximal cycling test
to measure mechanical efﬁciency in patients with COPD [6].
Furthermore, previous studies in COPD investigating the effect ofdietary nitrate onwalking performance showed no beneﬁcial effect
of dietary nitrate [33e36]. Overall, previous studies in COPD show
no convincing improvements on VO2 kinetics after nitrate ingestion
supporting the results of the current study (Supplemental Table 1).
Nitrate-rich supplements have increased in popularity among
elite and recreational athletes as they have been shown to improve
exercise capacity [17]. For this reason we hypothesized that nitrate
could be a useful intervention in COPD as adjunct to pulmonary
rehabilitation (PR) to increase the effects of exercise training.
However, the current study showed no improvement in cycling
endurance time. This corresponds to previous studies in COPD
(Supplemental Table 1), in which almost no effects of BRJ were
found on exercise performance. Only two studies showed signiﬁ-
cant improvements in submaximal cycling time and walking dis-
tance after acute ingestion of BRJ [31,35]. However, these studies
used prune juice and blackcurrant cordial as placebo, which is not a
robust placebo for BRJ. The effect of nitrate on exercise performance
has been shown to be enhanced supplemented in combination
with exposure to ultraviolet A radiation (UVA) and might be
inﬂuenced by seasonal differences [37]. Despite this study showed
no effect of nitrate on exercise performance in absence of UVA ra-
diation there seemed to be a trend towards reduced oxygen con-
sumption during exercise after nitrate ingestion without exposure
to UVA radiation. Therefore, we believe differences in UVA radia-
tion do not affect the results of the current study.
In the current study we recruited patients via advertisements,
which resulted in inclusion of normal-weight mild-to-moderate
COPD patients with moderate exercise impairment. Although pa-
tients were not referred to PR, all patients had a sedentary lifestyle
corresponding to the PA levels of patients referred to outpatient PR
[4]. Besides, patients hadmoderate decreasedmechanical efﬁciency,
which was signiﬁcantly lower compared to healthy controls from a
previous study by our group [10]. It has recently been shown that
gross efﬁciency is declined in COPDwith increasing disease severity
[38], which might suggest that more severe diseased COPD patients
might still beneﬁt fromdietary nitrate. However, in the current study
the response of sodium nitrate intake on mechanical efﬁciency was
not correlated with baseline mechanical efﬁciency (data not shown),
suggesting the results would be similar in case more severe patients
would be included. Therefore, we believe dietary nitrate is not the
promising adjunct to PR to elevate the training effects.
It has been established that in healthy and mostly young sub-
jects dietary nitrate supplementation can lower blood pressure
[14,15]. In the current study, nitrate supplementation caused no
changes in blood pressure and the meta-analysis also showed no
beneﬁcial effects of BRJ on blood pressure in the studies in COPD so
far (Fig. 6). Results may be inﬂuenced by current use of antihy-
pertensive medication. Two studies did not ﬁnd signiﬁcant re-
ductions in blood pressure in older hypertensive subjects that were
on antihypertensive medication [39,40], suggesting that an addi-
tional reduction in blood pressure might not occur in a group of
patients whose blood pressure is already well-controlled. In the
current study 7 patients were on antihypertensive medication.
However, excluding these patients from analyses did not inﬂuence
the results (data not shown). Another possible explanation for the
lack of changes in blood pressure might be the vascular ageing
process in which the capacity to convert nitrate to NO is possibly
reduced and the sensitivity of vascular smooth muscle cells to the
vasodilatory effects of NOmight be diminished [41]. This might also
be the case in COPD and it could be speculated that higher doses of
nitrate may be required to detect beneﬁcial effects on blood pres-
sure. Directly after the cycling test an increase in blood pressure
was observed, while after this phase (T4 and T5) the systolic blood
pressure was signiﬁcantly lower compared to baseline (T0) which
was consistent between both experimental groups at both days.
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nomenon which has previously been reported [42e44]. During the
recovery phase after exercise several mechanisms contribute to a
lower blood pressure including the mediated decreases in sympa-
thetic nerve activity, a decreased signal transduction from sympa-
thetic nerve activation into vasoconstriction as well as local
vasodilator mechanisms [45].
In the current study a dose of ~8 mmol nitrate per day was
applied. This dose was based on a dose-response study that
described a dose of 8.4 mmol/L was needed to signiﬁcantly change
oxygen parameters in recreationally active men [46]. Previous
studies have used a wide range in both the amount (i.e. dose and
duration) and source of nitrate supplemented and found contra-
dictory results [14,15,17,18], even in COPD [31e36]. In the current
study we used sodium nitrate as nitrate-rich supplement, since we
were interested in the effects of nitrate without needing to account
for unknown interactions with other interventional compounds in
the solution. Furthermore, sodium nitrate also reduced the oxygen
costs of exercise and lowered the blood pressure in healthy adults
[47e49]. Nevertheless, the current study shows that sodium nitrate
does not affect mechanical efﬁciency and blood pressure in COPD.
All previous studies in COPD used BRJ as a source of nitrate.
Although beneﬁcial effects on physiological responses of BRJ are
ascribed to the high nitrate content [19], it is still possible that ni-
trate is not the active nutrient after all or that nitrate interacts with
other compounds (e.g. vitamin C, potassium and polyphenols) in
BRJ, that cause the beneﬁcial effects. Indeed recent studies showed
greater blood pressure lowering and oxygen consumption lowering
effects of BRJ, rocket salad beverage or spinach beverage compared
to sodium nitrate in healthy adults [50,51]. However, the meta-
analysis performed in the current study shows no beneﬁcial ef-
fect of BRJ on blood pressure in patients with COPD. Therefore, the
results of the current study suggest no beneﬁcial effect of dietary
nitrate on blood pressure in patients with COPD and question the
efﬁcacy on oxygen consumption and exercise performance.
In the current study the effect of sodium nitrate intake on cardiac
biomarkers Hs-TNT, NT-proBNP and CK was investigated. Thesecardiac biomarkers are known biomarkers for the diagnosis of
myocardial injury and heart failure, are associated with increased
risk of cardiovascular and all-cause mortality and are known to in-
crease following exercise [52,53]. In the current study we indeed
show elevated levels of the cardiac markers after the cycling test,
however, the changes were unaffected by sodium nitrate ingestion.
Note that the observed higher Hs-TNT levels at the ﬁrst blood sam-
pling (early in themorning) can be ascribed to the diurnal rhythm of
Hs-TNT [54]. This study is also one of the ﬁrst studies investigating
the effect of sodium nitrate on skin and core temperature. Only the
effect of BRJ on oxygen cost of desert marching was previously
investigated and reported an elevated rise in core temperature after
nitrate ingestion without a change in skin temperature [55]. Based
on the expected vasodilatory effect of NOwe expected that core and
skin temperatureswouldhavebeen affected.However, no changes in
both body temperatures were observed. More studies are needed to
investigate the acute as well as the longer term effects of dietary
nitrate on cardiac markers and body temperatures.
In conclusion, both acute and 7-days sodium nitrate supple-
mentation does not increase mechanical efﬁciency, lower blood
pressure and modulate cardiac markers of mild-to-moderate pa-
tients with COPD. Dietary nitrate does not seem to be a promising
adjunct to PR to enhance the effects of exercise training.
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